Keratoacanthoma - 角化棘皮瘤
典型 角化棘皮瘤 (Keratoacanthoma)
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) 是一種常見的皮膚腫瘤，以其快速生長和自行消退的潛力而聞名。它通常發生在有曬傷史、年齡較大且皮膚白皙的男性身上。雖然常以切除或Mohs顯微手術治療，但仍有其他多種治療選擇。
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) 是一種低度惡性腫瘤，起源於皮膚的某些腺體，顯微鏡下其外觀與 squamous cell carcinoma (SCC) 相似。對於 KA 是否應歸類為侵襲性鱗狀細胞癌的變異形式，學界一直存在爭議。
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) 是人類第二常見的癌症類型，尤其常見於老年人。手術是治療鱗狀細胞癌的首選方式，但對於無法手術或選擇不手術的患者，可考慮病灶內治療等其他選項。傳統的病灶內治療，如 methotrexate 或 5‑fluorouracil，已被廣泛使用；然而，病灶內免疫療法與溶瘤病毒療法等新興方法的研究仍在持續進行。本文將探討 cSCC 的各種病灶內治療方式，從經典技術到前沿策略。
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
在顯微鏡下，角化棘皮瘤 (Keratoacanthoma) 與鱗狀細胞癌非常相似。雖然部分病理學家將角化棘皮瘤 (Keratoacanthoma) 歸類為獨特的實體而非惡性腫瘤，但約 6% 的臨床與組織學病例的角化棘皮瘤確實會進展為侵襲性鱗狀細胞癌。
○ 診斷與治療
#Dermoscopy
#Skin biopsy